CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
Trial details
- Registry ID
- NCT06708299
- Drugs studied
- CardiolRx
TrialRedline tracks 4 clinical trials sponsored by Cardiol Therapeutics Inc.: 1 Phase 3, 1 Phase 2 / 3, 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)NCT06708299 | CardiolRx | Recruiting | 2026-09-21Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk FactorsNCT04615949 | Cannabidiol, pharmaceutically produced with < 5 ppm THC | Terminated | 2022-11-30Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Impact of CardiolRx on Myocardial Recovery in Patients With Acute MyocarditisNCT05180240 | CardiolRx | Completed | 2025-01-31Actual |
| Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)NCT05494788 | CardiolRx | Completed | 2024-06-15Actual |
Names as written in the registry records.
NCT06708299 · Cardiol Therapeutics Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Recurrence of pericarditis. After: Measure: time to pericarditis recurrence.
NCT05180240 · Cardiol Therapeutics Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: extracellular volume (ECV) Measure: Global longitudinal Strain (GLS). After: Measure: Extracellular Volume (ECV) Measure: Global Longitudinal Strain (GLS).
NCT04615949 · Cardiol Therapeutics Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: All-cause Mortality. After: Measure: Composite of All-cause Mortality, Requirement for ICU Admission and/or Ventillatory Support and Cardiovascular Complications.